Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | aerobic-type carbon monoxide dehydrogenase subunit CoxL_2 | 0.0289 | 0.2516 | 0.4783 |
Loa Loa (eye worm) | integrin alpha pat-2 | 0.0523 | 0.6833 | 0.6614 |
Echinococcus multilocularis | integrin alpha 3 | 0.026 | 0.1989 | 0.2977 |
Mycobacterium tuberculosis | Probable carbon monoxyde dehydrogenase (large chain) | 0.0289 | 0.2516 | 1 |
Schistosoma mansoni | integrin alpha | 0.0339 | 0.3448 | 0.728 |
Schistosoma mansoni | integrin beta subunit | 0.0409 | 0.4737 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0257 | 0.1926 | 0.1368 |
Mycobacterium ulcerans | carbon monoxide dehydrogenase | 0.0406 | 0.4669 | 1 |
Mycobacterium ulcerans | carbon monoxyde dehydrogenase large chain CoxL | 0.0289 | 0.2516 | 0.4783 |
Trichomonas vaginalis | xanthine dehydrogenase, putative | 0.0612 | 0.8477 | 0.5 |
Echinococcus multilocularis | integrin beta 2 | 0.0515 | 0.6682 | 1 |
Trichomonas vaginalis | xanthine dehydrogenase, putative | 0.0612 | 0.8477 | 0.5 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.0339 | 0.3448 | 0.1886 |
Mycobacterium ulcerans | carbon monoxyde dehydrogenase medium chain CoxM | 0.0207 | 0.1006 | 0.1125 |
Loa Loa (eye worm) | integrin beta-2 | 0.0695 | 1 | 1 |
Echinococcus granulosus | integrin beta 2 | 0.0515 | 0.6682 | 1 |
Mycobacterium ulcerans | aerobic-type carbon monoxide dehydrogenase subunit CoxM_2 | 0.0207 | 0.1006 | 0.1125 |
Loa Loa (eye worm) | hypothetical protein | 0.0266 | 0.2105 | 0.156 |
Trichomonas vaginalis | aldehyde oxidase, putative | 0.0612 | 0.8477 | 0.5 |
Echinococcus granulosus | integrin alpha 3 | 0.026 | 0.1989 | 0.2977 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 0.1 ug ml-1 | Antibacterial activity of the compound against Escherichia coli (H560) | ChEMBL. | 3005575 |
MIC (functional) | = 0.1 ug ml-1 | Antibacterial activity of the compound against Escherichia coli (H560) | ChEMBL. | 3005575 |
MIC (functional) | = 0.4 ug ml-1 | Antibacterial activity of the compound against Escherichia coli (vogel) | ChEMBL. | 3005575 |
MIC (functional) | = 0.4 ug ml-1 | Antibacterial activity of the compound against Escherichia coli (vogel) | ChEMBL. | 3005575 |
MIC (functional) | = 1.6 ug ml-1 | Antibacterial activity against Klebsiella pneumonia (MGH-2) | ChEMBL. | 3005575 |
MIC (functional) | = 1.6 ug ml-1 | Antibacterial activity against Klebsiella pneumonia (MGH-2) | ChEMBL. | 3005575 |
MIC (functional) | = 3.1 ug ml-1 | Antibacterial activity of the compound against Pseudomonas aeruginosa (UI-18) | ChEMBL. | 3005575 |
MIC (functional) | = 3.1 ug ml-1 | Antibacterial activity of the compound against Staphylococcus aureus (H228) | ChEMBL. | 3005575 |
MIC (functional) | = 3.1 ug ml-1 | Antibacterial activity of the compound against Pseudomonas aeruginosa (UI-18) | ChEMBL. | 3005575 |
MIC (functional) | = 3.1 ug ml-1 | Antibacterial activity of the compound against Staphylococcus aureus (H228) | ChEMBL. | 3005575 |
MIC (functional) | = 7.5 ug ml-1 | MIC of the compound at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 microg/mL by using Gyrase Induced DNA-Cleavage assay | ChEMBL. | 3005575 |
MIC (functional) | = 7.5 ug ml-1 | MIC of the compound at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 microg/mL by using Gyrase Induced DNA-Cleavage assay | ChEMBL. | 3005575 |
MIC (functional) | = 12.5 ug ml-1 | Antibacterial activity of the compound against Streptococcus pneumoniae (SV-1) | ChEMBL. | 3005575 |
MIC (functional) | = 12.5 ug ml-1 | Antibacterial activity of the compound against Streptococcus pneumoniae (SV-1) | ChEMBL. | 3005575 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.